

AWARD NUMBERS: W81XWH-14-1-0555

TITLE: Development of Personalized Cancer Therapy for Men with Advanced Prostate Cancer

PRINCIPAL INVESTIGATOR: Dr. Arul M. Chinnaiyan (Partnering PI)

CONTRACTING ORGANIZATION: University of Michigan
Ann Arbor, MI 48109-5940

REPORT DATE: October 2016

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release, distribution is unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE October 2016		2. REPORT TYPE Annual		3. DATES COVERED 09/22/2015-09/21/2016	
4. TITLE AND SUBTITLE Development of Personalized Cancer Therapy for Men with Advanced Prostate Cancer				5a. CONTRACT NUMBER N/A	
				5b. GRANT NUMBER W81XWH-14-1-0555	
				5c. PROGRAM ELEMENT NUMBER N/A	
6. AUTHOR(S) Nora M. Navone, M.D., Ph.D. Arul Chinnaiyan, M.D., Ph.D. E-Mail: nnavone@mdanderson.org and arul@med.umich.edu				5d. PROJECT NUMBER N/A	
				5e. TASK NUMBER N/A	
				5f. WORK UNIT NUMBER N/A	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) The University of Texas University of Michigan MD Anderson Cancer Center 1400 E. Medical Center Drive 1515 Holcombe Blvd. Room 5316 CC Houston, TX 77030-4009 Ann Arbor, MI 48109-5940				8. PERFORMING ORGANIZATION REPORT NUMBER N/A	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S) N/A	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S) N/A	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT The purpose of this study is to develop a strategy to identify molecular markers of response of advanced prostate cancer to specific therapies using clinically relevant prostate cancer patient-derived xenografts (PDXs) that are responders and nonresponders to these therapies. We will identify genomic alterations via integrative genomic analysis of these PDXs. The MD Anderson and Michigan teams will interact closely to analyze results and generate a responder ID profile hypothesis. The validity of the responder ID profiles will be assessed in clinical trials. When we were in the process of performing our studies at the MD Anderson site, we were informed that there was a miscommunication between MD Anderson and USAMRMC Animal Care and Use Review Office (ACURO) and that the animal protocols had not been reviewed by ACURO. Thus we were asked to stop all studies and to return all funds utilized for the project as this could not be executed until the animal protocol is approved by ACURO. In May 2016, we had our animal protocol approved and we started our studies.					
15. SUBJECT TERMS Bone metastases, targeted therapy, prostate cancer					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT Unclassified	18. NUMBER OF PAGES 30	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT Unclassified	b. ABSTRACT Unclassified	c. THIS PAGE Unclassified			19b. TELEPHONE NUMBER (include area code)

TABLE OF CONTENTS

	Page
1. Introduction.....	4
2. Keywords	4
3. Accomplishments.....	4
4. Impact.....	11
5. Changes/Problems.....	11
6. Products.....	12
7. Participants & Other Collaborating Organizations.....	13
8. Special Reporting Requirements	30
9. Appendices.....	n/a

Development of Personalized Cancer Therapy for Men with Advanced Prostate Cancer

Annual Report

1. INTRODUCTION

Castration-resistant progression and bone metastasis are hallmarks of advanced prostate cancer, for which there is no cure. Recent clinical trials have had encouraging results but only in subsets of patients, and emergence of treatment resistance is inevitable for most patients. Thus, strategies for selecting patients who are responders to treatment and identifying effective combination treatment strategies are urgently needed. The purpose of this study is to develop a strategy for identifying molecular markers of response of advanced prostate cancer to specific therapies. To achieve this goal, we will use clinically relevant prostate cancer patient-derived xenografts (PDXs) that are responders and nonresponders (primary and secondary resistance) to therapies that had demonstrated clinical activity. We will identify genomic alterations via integrative genomic analysis of these PDXs. The MD Anderson and the Michigan Center for Translational Pathology (MCTP) teams will interact closely to analyze integrative genomic analysis results to generate a responder ID profile hypothesis. The validity of the responder ID profiles will be assessed in clinical trials.

2. KEYWORDS

Bone metastases, targeted therapy, prostate cancer

3. ACCOMPLISHMENTS

What were the major goals of the project?

Specific Aim 1: Develop PDXs that reflect the lethal form of prostate cancer.

Major Task 1: Develop clinically relevant prostate cancer xenografts and comprehensively characterize the xenografts and human donor tumors.

Subtask 1: Establish new and expand existing prostate cancer PDXs from bone metastases or primary tumors. **(1-24 months, Dr. Nora Navone)**

Subtask 2: Assess the histopathologic and immunohistochemical characteristics of the prostate cancer xenografts and human tumors of origin. **(1-20 months, Drs. Navone and Arul Chinnaiyan)**

- Select currently available and recently developed (subtask 1) PDXs derived from primary prostate cancer or bone metastases.
- Perform histopathologic and immunohistochemical characterization of selected prostate cancer PDXs.
- Assess the fidelity of the prostate cancer PDXs to the human tumors of origin.

Specific Aim 2: Develop a responder ID profile hypothesis according to the treatment responsiveness of fully characterized prostate cancer PDXs.

Major Task 2: Identify prostate cancer PDX responders and nonresponders (primary resistance) to treatment with specific drugs and establish treatment-resistant PDX lines.

Subtask 1: Identify prostate cancer PDX responders and nonresponders (primary resistance) to abiraterone plus enzalutamide and establish lines of PDXs resistant to abiraterone plus enzalutamide (acquired resistance). **(1-24 months, Dr. Navone)**

Subtask 2: Identify prostate cancer PDX responders and nonresponders (primary resistance) to cabozantinib and develop cabozantinib-resistant PDX lines (acquired resistance). **(1-24 months, Dr. Chinnaiyan)**

Subtask 3: Identify prostate cancer PDX responders and nonresponders (primary resistance) to dovitinib and develop dovitinib-resistant PDX lines (acquired resistance). **(1-24 months, Dr. Navone)**

Major Task 3: Perform integrative genomic analysis of responder and primary and secondary treatment-resistant prostate cancer PDXs.

Subtask 1: Send flash-frozen specimens of responder and primary and secondary treatment-resistant prostate cancer PDXs and normal DNA obtained from human donor tumors to the MCTP for whole-genome and transcriptome sequencing (RNA-seq) and for targeted whole-exome sequencing. **(8-24 months, Drs. Chinnaiyan, Dan Robinson, and Yi-Mi Wu)**

Subtask 2: Perform data analysis to identify a list of genomic alterations deemed clinically relevant. **(12-24 months, Drs. Chinnaiyan, Robinson, and Wu)**

Subtask 3: Identify potential pathways of resistance that can be targeted in combination trials based on clinically relevant genomic alterations in therapy-responsive and -resistant prostate cancer PDXs. **(12-24 months, Drs. Navone, John Araujo, Christopher Logothetis, Drs. Chinnaiyan, Robinson, and Wu)**

Subtask 4: Subject prostate cancer PDXs to therapies targeting pathways identified in subtask 3 in combination with abiraterone and enzalutamide, cabozantinib, or dovitinib, giving priority to drugs currently in prostate cancer clinical trials at MD Anderson or the University of Michigan. **(12-34 months, Drs. Navone and Chinnaiyan)**

Subtask 5: Generate a responder ID profile. This hypothesis proposes a link between therapy responses (responder or nonresponder) of prostate cancer PDXs and the identified clinically relevant genomic alterations. The hypothesis will be tested in Specific Aim 3. **(12-24 months, Drs. Navone, Araujo, Logothetis, Bradley Broom and Drs. Chinnaiyan, Robinson, and Wu)**

Specific Aim 3: Validate the responder ID profile hypothesis in a clinical trial.

Major Task 3: Test this hypothesis by analyzing bone biopsy specimens and/or bone marrow aspirates obtained from sites with bone metastases in patients enrolled in the clinical studies listed in the grant.

Subtask 1: Assess the presence of genomic alterations that define the responder ID profile hypothesis in FFPE bone marrow core biopsy specimens and/or bone marrow aspirates (soluble fractions) obtained before and/or after 8 weeks of treatment. **(24-34 months, Drs. Navone, Araujo, Logothetis, Patricia Troncoso, Broom, and Drs. Chinnaiyan, Robinson, and Wu)**

- Abiraterone and enzalutamide clinical study (NCT01650194; PI, C. J. Logothetis). Three arms: enzalutamide combined with abiraterone (n=20), enzalutamide (n=20), and abiraterone (n=20).
- Cabozantinib clinical study (NCT00940225; PI, P. Corn at MD Anderson). N=21.
- Dovitinib clinical study (NCT00831792; PI, P. Corn). N=40.

Subtask 2: Examine the results of the bone biopsy specimen and/or bone marrow aspirate analysis (performed by our collaborating statistician, Dr. Broom, in a close interaction with **Drs. Navone, Logothetis, Araujo, Troncoso, and Chinnaiyan**) to determine whether the patients' responses to therapy were predicted by our responder ID profile hypothesis. (24-34 months)

What was accomplished under these goals?

Major Task 1. As previously mentioned, when we were in the process of performing our studies at the MD Anderson site, we were informed that there was a miscommunication between MD Anderson and USAMRMC Animal Care and Use Review Office (ACURO) and that the animal protocols had not been reviewed by ACURO. Thus we were asked to stop all studies and return all funds utilized thus far for the project as this could not be executed until the animal protocol is approved by ACURO. In May 2016, we had our animal protocol approved and we started our studies. We thus started the establishment of new PDXs derived from the prostate and bone metastases. **Table 1** outlines the tumor tissue implanted in mice for PDX development since May 2016. Many of these are listed in Passage 0 because they did not produce a tumor large enough to be passaged to a second mouse (Passage 1) (MD Anderson site, Dr. Navone's Laboratory).

The specific objective is to have a panel of PDXs that would reflect human prostate cancer so that they can be utilized for our preclinical studies. However, given that PDXs derived from prostate cancer have a slow growth rate. For the proposed studies, we will use PDX previously established in our laboratory. Nevertheless, we will continue to develop PDXs and these PDXs will also be made available to the scientific community through a material transfer agreement.

We have selected prostate cancer PDXs derived bone metastases (MDA PCa 118b and MDA PCa 183) and primary prostate cancer (MDA PCa 180-30 and MDA PCa 149-1) for which we have assessed the fidelity with the human tumor of origin. We will utilize these lines in the first preclinical studies. We will continue the characterization with the newly established lines.

Table 1. Prostate cancer tissue specimen implanted into mice for PDX developed since May 2016							
Date of tissue implantation in mice	Patient Number	Clinical Stage	Human Donor Tumor Information			PDX Information	
			Procedure Type	Pathology Diagnosis	Tumor Site	PDX Name (MDA PCa)	Current Passage
5/23/2016	327	Metastatic	Biopsy	Metastatic Adenocarcinoma	Bone Marrow	327-1	0
			Venipuncture	N/A	CTC	327-2	0
6/9/2016	328	Primary	Venipuncture	N/A	CTC	328-0	0
			Transurethral Resection	Small Cell Carcinoma with Neuroendocrine Differentiation	Prostate	328-1	0
						328-3	0
						328-5	0
7/5/2016	329	Primary	Radical Prostatectomy	Adenocarcinoma	Prostate	329-9	0
7/20/2016	330	Metastatic	Biopsy-Core	Metastatic Adenocarcinoma	Bone	330-A	0
7/29/2016	331	Metastatic	Biopsy-Core	Atypical Cells	Bone	331-A	0
8/17/2016	332	Metastatic	Biopsy-Core	Carcinoma	Liver	332-B	0
9/2/2016	333	Locally Advanced	Resection	Adenocarcinoma	Soft Tissue	333-1	0
9/2/2016	334	Metastatic	Venipuncture	N/A	CTC	334-1	0
9/9/2016	335	Metastatic	Venipuncture	N/A	CTC	335-1	0
9/13/2016	336	Locally Advanced	Biopsy-Core	Adenocarcinoma	Soft Tissue	336-A	0
10/3/2016	337	Metastatic	Biopsy-Core	Metastatic Carcinoma with Neuroendocrine Differentiation	Liver	337-A	0
10/11/2016	338	Metastatic	Biopsy-Core	Metastatic Adenocarcinoma	Bone	338-B	0
10/11/2016	339	Metastatic	Biopsy-Core	Metastatic Adenocarcinoma	Lymph Node	339-A	0

Major Task 2. Under this task our objective is to identify prostate cancer PDX responders and nonresponders (primary resistance) to treatment with specific drugs and establish treatment-resistant PDX lines.

Subtask 2: Identify prostate cancer PDX responders and nonresponders (primary resistance) to cabozantinib and develop cabozantinib-resistant PDX lines (acquired resistance).

We tested MET protein level in various prostate cancer cell lines and found MET levels to be higher in AR negative versus AR positive lines. In particular, we noted a higher MET protein level in AR negative 146-10 PDX than in AR positive 146-12 PDX model (**Fig. 1**).




Fig. 1. MET is highly expressed in AR negative prostate cancer cell lines and PDX models. Western blot analysis of MET protein expression in various prostate cell lines with different AR status and two PDX models.




Fig. 2. MET expression predicts sensitivity to MET inhibitor Cabozantinib (Cabo). Invasion assay was performed in the presence of HGF and/or various treatment doses of Cabo in MET high/low and AR-negative/positive prostate cancer cells for 24 hours.

Based on our cell line data and matching MET/AR status, we can postulate that AR-negative/MET high PDXs (i.e. PDX 146-10), like DU145 and PC3 (**Fig. 2**), should respond to Cabo, while AR-positive/MET low PDXs (i.e. PDX146-12), like VCaP and LNCaP (**Fig. 2**), should be non-responders. In the future, we will test PDX146-10 and PDX 146-12 Cabo responsiveness in vivo. (University of Michigan, Dr. Chinnaiyan Lab).

We tested in prostate cell lines LNCaP and VCaP. We are in the process of identifying prostate cancer PDX responders and not responders to cabozantinib.

Subtask 3: Identify prostate cancer PDX responders and nonresponders (primary resistance) to dovitinib and develop dovitinib-resistant PDX lines (acquired resistance) (MD Anderson, Dr. Navone Laboratory).

The impetus for the studies with Dovitinib (Novartis Pharma), a FGFR inhibitor, was that Dovitinib demonstrated antitumor activity in a clinical study of men with prostate cancer (*Sci Transl Med* 6(252):252ra122, 9/2014). However, Dovitinib was withdrawn and a pan-FGFR kinase inhibitor, which is currently in a clinical phase I trial (NVP-BGJ398; Novartis Pharmaceuticals), is the lead compound being tested as anticancer therapy by Novartis. In addition, in an agreement with Janssen Pharmaceutical Companies of Johnson & Johnson we obtained a pan-FGFR inhibitor from (JNJS 42756493) to test in a preclinical setting.

Prior to May 2016 (before the ACURO review as in place), we tested the antitumor activity of JNJS 42756493 and NVP-BGJ398 against prostate cancer PDXs growing in bone. For this we used MDA PCa 118b PDX because they were responders in the study conducted using Dovitinib. We found that JNJS 42756493 (but not NVP-BGJ398) had antitumor activity against MDA PCa 118b PDX growing in the bone of mice. Briefly, a preclinical study using cells derived from MDA PCa 118b PDX growing in the bone of male SCID mice and treated with NVP-BGJ398 and JNJS 42756493 indicated minimal antitumor effect of NVP-BGJ398 and potent antitumor effect of JNJS 42756493. These results were outlined in our previous progress report, but we had to stop the studies and funds supporting these studies had to be restored to DOD until ACURO was reviewed and approved. At that time we had initiated a second preclinical study treating MDA PCa 118b growing in the bone of mice with JNJS 42756493 with the goal of setting aside tissue samples for comprehensive genomic analyses and will also develop resistant lines. We have resumed these studies in May 2016 and the experiments are ongoing.

Major Task 3: Perform integrative genomic analysis of responder and primary and secondary treatment-resistant prostate cancer PDXs (University of Michigan, Dr. Chinnaiyan Laboratory, and MD Anderson, Dr. Navone Laboratory).

Subtask 1: Dr. Arul Chinnaiyan at the University of Michigan assessed expression levels of FGFR1 transcripts by RNA sequencing of 183 human prostate cancer samples and of PDXs. The length of the

Most abundant expressed transcripts	Predicted protein length
ENST00000326324 ENST00000356207 ENST00000397103	731-733 aa
ENST00000397091 ENST00000397108 ENST00000397113 ENST00000425967 ENST00000532791	820-853 aa

Table 2. Different prostate cancer tissue samples express different FGFR1 isoforms. RNA sequencing analysis of FGFR1 transcripts in human prostate cancer samples and PDXs (performed in collaboration with Dr. Arul Chinnaiyan, MCTP).

protein isoforms related to the predicted transcripts, found by RNA sequencing, range between 731 to 853aa. When performing the analysis, we identified eight different protein coding transcript to be the most abundantly expressed, namely ENST00000326324; ENST00000356207; ENST00000397103 (with a predicted protein length of 731 to 733 aa) and ENST00000397091; ENST00000397108; ENST00000397113; ENST00000425967; ENST00000532791 (with a predicted protein length of 820 to 853aa); probably reflecting FGFR1alpha and FGFR1 beta isoforms (**Table 2**). The studies presented here will thus focus in these two best-characterized isoforms.

Since these isoforms are predicted from RNA sequencing, we at the MD Anderson site have first validated these findings by RT-PCR with specific primers using PDXs and prostate cancer cell lines. We subsequently assessed the expression of FGFR1alpha and beta in three prostate cancer cell lines (PC3, DU145 and C4-2B) and seven prostate cancer PDXs (MDA PCa 2b, MDA PCa 118b, MDA PCa 155-12; MDA PCa 146-10; MDA PCa 146-12; MDA PCa 150-3 and MDA PCa 183) derived from primary prostate cancer, bone metastases and brain metastases and reflecting the typical adenocarcinoma as well as, adenocarcinomas with neuroendocrine differentiation and small cell carcinomas of prostate cancer. We found that all PDXs express primarily FGFR1alpha isoform while prostate cancer cell lines express FGFR1beta (**Fig. 3**).




Fig. 3. Levels of FGFR1 alpha and beta mRNA expression in prostate cancer cell lines and prostate cancer PDXs were assayed by RT-PCR.

In transient transfections we studied differences in the signaling pathways activated by the two isoforms. For that we transiently transfected two prostate cancer cell lines, PC3 and C4-2B, with empty vector (EV), FGFR1alpha (NM_023110.2) or FGFR1beta (NM_023105.2). We subsequently treated the cells with vehicle, FGF2 or FGF9 to induce the pathway and analyzed the results by Western blot. We observed that only FGFR1 alpha expression (not FGFR1 beta) results in its phosphorylation and induces PLCγ phosphorylation in both cell lines (**Fig. 4**). In PC3 cells, we found that total FGFR1 expression (relative to a loading control) was similar in cells transfected with FGFR1beta or FGFR1alpha. Levels of p-FGFR1 were high in untreated cells transfected with FGFR1alpha, but no further induction was observed after treatment with FGF2 or FGF9. However, p-FGFR1 expression was almost undetectable in untreated cells expressing FGFR1beta and was slightly induced by FGF2 but not by FGF9. p-PLCγ expression was found only in cells expressing FGFR1alpha. Similar results were found in C4-2B (**Fig. 4**)

Further *in vitro* studies show higher proliferation rates for PC3 cells expressing isoform alpha when evaluated by direct cell counting with Trypan blue exclusion method compared to cells expressing beta and control cells (**Fig. 5**). Also, invasion assays using Matrigel invasion chambers show that both PC3 cells with alpha and beta isoform invade more than empty vector control cells (data not shown).

Based on these studies, we hypothesize that FGFR1 alpha and beta confers different phenotypes to prostate cancer cells and this may underlay, at least in part, prostate cancer heterogeneity, pattern of progression, and differences of response to FGFR1 inhibitor.




Fig. 4. Expression of FGFR1, P-FGFR1 and signaling molecules downstream of FGFR1 evaluated by Western blot. p-PLCγ expression is only found in cells expressing FGFR1 alpha. Similar results were obtained in three independent experiments.




Fig. 5. Growth of PC3 FGFR1 stable cell lines was assessed by cell number determination through direct cell counting with Trypan-blue. * Significant difference, P < 0.05 respect to other groups

What opportunities for training and professional development has the project provided?

Nothing to Report

How were the results disseminated to communities of interest?

Nothing to Report

What do you plan to do during the next reporting period to accomplish the goals?

During the next period, Dr. Navone will develop JNJS 42756493 resistant PDXs and will send flash-frozen specimens of responder and primary and secondary treatment-resistant prostate cancer PDXs and normal DNA obtained from human donor tumors to the MCTP for whole-genome and transcriptome sequencing (RNA-seq) and for targeted whole-exome sequencing.

We will Identify prostate cancer PDX responders and nonresponders (primary resistance) to cabozatinib, abiraterone plus enzalutamide and establish lines of PDXs resistant (acquired resistance).

We will identify potential pathways of resistance that can be targeted in combination trials based on clinically relevant genomic alterations in therapy-responsive and -resistant prostate cancer PDXs.

4. IMPACT**What was the impact on the development of the principal discipline(s) of the project?**

We have established a series of PDXs that will be made available to the scientific community for research.

What was the impact on other disciplines?

Nothing to Report

What was the impact on technology transfer?

Nothing to Report

What was the impact on society beyond science and technology?

Nothing to Report

5. CHANGES/PROBLEMS**Changes in approach and reasons for change**

No changes

**Actual or anticipated problems or delays and actions or plans to resolve them
Changes that had a significant impact on expenditures**

There was a miscommunication between MD Anderson and USAMRMC Animal Care and Use Review Office (ACURO) and that the animal protocols had not been reviewed by ACURO. Thus we were asked to stop all studies and to return all funds utilized thus far for the project as this could not be executed until the animal protocol is approved by ACURO. In May 2016, we had our animal protocol approved and we started our studies. As a result, we had a significant delay in the initiation of our studies and a positive balance in our budget that we request to carry forward to the next budget period. We will compensate this delay in the coming year.

Significant changes in use or care of human subjects, vertebrate animals, biohazards, and/or select agents

No changes

Significant changes in use or care of human subjects

No changes

Significant changes in use or care of vertebrate animals

No changes

Significant changes in use of biohazards and/or select agents

No changes

6. PRODUCTS

Publications, conference papers, and presentations

Nothing to report

Journal publications

Nothing to report

Books or other non-periodical, one-time publications

Nothing to report

Other publications, conference papers and presentations

Nothing to report

Website(s) or other Internet site(s)

Nothing to report

Technologies or techniques

Nothing to report

Inventions, patent applications, and/or licenses

Nothing to report

Other Products

Development of PDXs that will be made available to the scientific community.

7. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS

What individuals have worked on the project?

The University of Texas MD Anderson Cancer Center

Name:	Nora M. Navone
Project Role:	Principal Investigator
Nearest person month worked:	1.80 calendar months
Contribution to Project:	Dr. Navone is responsible for designing the experiments, evaluating the results, coordinating the personnel's efforts related to all in vivo studies in mice, and preparing prostate cancer cells derived from human prostate cancer xenografts. She closely interacts with Dr. Chinnaiyan to integrate the research efforts within this project.
Funding Support:	Funding support is provided from this award.

Name:	John Araujo
Project Role:	Co-Principal Investigator
Nearest person month worked:	0.12 calendar months
Contribution to Project:	Dr. Araujo provides clinical-related data on the follow-up of men whose prostate cancer was the source of prostate cancer xenografts or was a tissue specimen used for genomic analysis. He works closely with Dr. Navone in the analysis of these data and their correlation with molecular studies.
Funding Support:	Funding support is provided from this award.

Name:	Bradley Broom
Project Role:	Collaborator
Nearest person month worked:	0.24 calendar months
Contribution to Project:	Dr. Broom provides expertise in biostatistics to analyze the data emerging from the preclinical studies, including the molecular studies, and relate them to the findings emerging from the clinic.
Funding Support:	Funding support is provided from this award.

Name:	Estefania Labanca
Project Role:	Graduate Research Assistant-GSBS
Nearest person month worked:	3.60 calendar months
Contribution to Project:	Upon Xinhai Wan's departure from the department, Ms. Labanca will be responsible for intrabone injection of prostate cancer cells in mice and the in vivo experiments involving laboratory animals. She will perform the immunohistochemical studies of tissue samples and the molecular and cell biology studies related to the in vivo studies. Dr. Wan trained her in these techniques before he left.
Funding Support:	Salary support will be provided from this grant upon DOD approval.

Name:	Xinhai Wan
Project Role:	Collaborator
Nearest person month worked:	4.80 calendar months

Contribution to Project:	Dr. Wan was responsible for intrabone injection of prostate cancer cells in mice and the in vivo experiments involving laboratory animals. He performed the immunohistochemical studies of tissue samples and the molecular and cell biology studies related to the in vivo studies. Dr. Wan trained Estefania Labanca, Graduate Research Assistant, in these techniques before he left and she will be responsible for these studies now
Funding Support:	Funding support was provided from this award up to 7/31/2016 when Dr. Wan left the department to serve as a Sr. Research Scientist. Since he is no longer working with Dr. Navone his effort was removed effective 8/1/2016.

Name:	Jun Yang
Project Role:	Research Laboratory Coordinator
Nearest person month worked:	3 calendar months
Contribution to Project:	Ms. Wang is responsible for preparing cell and tumor lines for the planned experiments and for performing assays involving molecular and cell biology techniques. She also provides technical support for the experiments involving in vivo manipulation of animals and will order supplies.
Funding Support:	Funding support is provided from this award.

The University of Michigan

Name:	Arul Chinnaiyan
Project Role:	Partnering PI
Nearest person month worked:	0.60 calendar months
Contribution to Project:	Responsible for overall oversight of the project and co-directs the CLIA-certified lab. He is accountable that the project produces high quality data and coordinates the efforts of the personnel and collaborators. He closely interacts with Dr. Navone to integrate the research efforts within this project.
Funding Support:	He receives salary from the Howard Hughes Medical Institute.

Name:	Dan Robinson
Project Role:	Co-Investigator
Nearest person month worked:	1.92 calendar months
Contribution to Project:	Oversees preparation of sequencing libraries, quality control, and provides expertise in genome biology.
Funding Support:	Funding support is provided from this award.

Name:	Yi-Mi Wu
Project Role:	Co-Investigator
Nearest person month worked:	3.60 calendar months
Contribution to Project:	Guide the project's research development and facilitate interpretation of sequence data.
Funding Support:	Funding support is provided from this award.

Name:	Xiaoxuan Dang
Project Role:	Sequencing Technician
Nearest person month worked:	3.0 calendar months
Contribution to Project:	Assisting in library generation and sequencing.
Funding Support:	Funding support is provided from this award.

Name:	Robert Lonigro
Project Role:	Bioinformatics Analyst
Nearest person month worked:	2.40 calendar months
Contribution to Project:	Provides bioinformatic analysis in the context of candidate gene nominations.
Funding Support:	Funding support is provided from this award.

Name:	Jean Tien
Project Role:	Research Investigator
Nearest person month worked:	2.40 calendar months
Contribution to Project:	PDX models
Funding Support:	Funding support is provided from this award.

Has there been a change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period?

Yes, the active other support for key personnel has changed. Several grants have expired and new ones have been awarded. We are including the updated active other support below for key personnel.

MD ANDERSON KEY PERSONNEL

NAVONE, Nora

CURRENT

Movember

Title:

Supporting Agency:

Grants Officer:

Time Commitment:

Performance Period:

Level of Funding:

Goals:

Specific Aims:

Role:

(Navone)

GAP1 Xenograft Project Integration Plan: Development of Prostate Cancer Xenografts to Model Human Prostate Cancer

PCF/Movember

Dr. Mark Buzza, Movember Foundation-1250 Fourth Street,
Santa Monica CA 90401

1% effort, 0.12 calendar

01/01/2014-12/30/2016 NCE

t

The ultimate goal is to create a catalog of prostate cancer patient-derived xenografts developed in different institutions around the world. This catalog would contain basic information of the prostate cancer patient-derived xenografts associated to expression of genes most frequently altered in prostate cancer as assessed by immunohistochemical analyses of tissue microarrays.

Not applicable

Principal Investigator

SINF	(Navone)
Title:	German Cancer Research Center National Center for Tumor Diseases
Time Commitment:	10% effort, 1.20 calendar (unsalaried)
Supporting Agency:	MD Anderson Sister Institution Network Fund (SINF)
Grants Officer:	Govind Narasimhan, Director, Res. Finance
Performance Period:	11/01/2013-11/30/2016
Level of Funding:	
Goals:	The ultimate goal is not only to obtain a more in-depth understanding of the signaling circuitry that drives osteoblastic bone metastasis in castration-resistant prostate cancer patients, but also to provide a rational basis for the use of FGFR-targeted agents and a model system of anticipated resistance mechanisms.
Specific Aims:	1) To assess the effects of FGFR-targeted therapies on osteoblastic prostate cancer bone metastases in a patient-derived xenograft mouse model. 2) To characterize the response to FGFR-targeted therapies with a focus on chromosomal instability. 3) To analyze potential genetic and functional resistance mechanisms to FGFR-targeted therapies in the mouse model and in paired patient biopsy samples.
Role:	Principal Investigator
 Janssen	 (Navone)
Title:	FGFR Inhibitors in Prostate Cancer Bone Metastasis
Time Commitment:	15% effort, 1.80 calendar
Supporting Agency:	Janssen Research and Development
Grants Officer:	James Bischoff, Senior Director
Performance Period:	08/14/2014-07/31/2017
Level of Funding:	
Description:	This program's goal is to test the antitumor efficacy of a pan-FGFR inhibitor (JNJS 42756493) against patient-derived xenografts developed in my laboratory.
Specific Aims:	1) Assess the efficacy of pan FGFR inhibitor(s) (company material) on prostate cancer PDX growing in the bone of male SCID mice. 2) Assess the efficacy of company material on the growth of prostate cancer PDX in bone of male SCID mice. 3) Screen tissue microarrays (TMAs) containing prostate cancer PDXs for expression of targets of interest to company.
Role:	Principal Investigator
 PCa Moon Shot	 (Logothetis/Thompson)
Title:	Flagship 1: Optimizing Androgen Signaling Inhibition to Transition from a Treatment to Curative Paradigm
Time Commitment:	5% effort, 0.60 calendar
Supporting Agency:	MD Anderson Moon Shot Program
Grants Officer:	Govind Narasimhan, Director, Res. Finance;

Performance Period:	09/01/2016-08/31/2017
Level of Funding:	
Goals:	1) To determine the two year cancer free survival of men treated with AA, and androgen ablation + androgen biosynthesis inhibition. 2) To link the outcomes in subproject 1 to the biologic characterization of the primary, blood, of the study patients in goal 1 and pretreated cancers to outcome(s). 3) Initiate two clinical trials in priority targets identified in “curative intent trials“ and apply the findings to develop marker driven combinations or sequences of therapy in select patients.
Specific Aims:	Same as above
Role:	Co-Investigator
PCa Moon Shot	(Logothetis/Thompson)
Title:	Flagship 2: Targeting the Immune and Non-Immune Tumor-Associated Microenvironments in Prostate Cancer
Time Commitment:	5% effort, 0.60 calendar
Supporting Agency:	MD Anderson Moon Shot Program
Grants Officer:	Govind Narasimhan, Director, Res. Finance
Performance Period:	09/01/2016-08/31/2017
Level of Funding:	The ultimate goal is to rationally integrate bone-targeting agents with immune checkpoint therapies to cure metastatic prostate cancer by continuing to implement our co-clinical approach with novel preclinical models and patient samples acquired from our biomarker-driven clinical trials.
Goals:	
Specific Aims:	1) To identify biomarkers within the secretome predictive of responsiveness to cabozantinib. 2) To identify biomarkers within the bone secretome predictive for earlier clinical intervention with radium-223 in patients with metastatic prostate cancer to the bone and in combination with other targeted therapies. 3) To rationally integrate immune checkpoint strategies with cabozantinib and radium-223.
Role:	Co-Investigator
W81XWH-14-1-0554	(Navone)
Title:	Development of Personalized Cancer Therapy for Men with Advanced Prostate Cancer
Time Commitment:	15% effort, 1.80 calendar
Supporting Agency:	DOD-PCRP Synergistic Idea Development Award
Grants Officer:	Janet P. Kuhns
Performance Period:	09/22/2014-09/21/2017
Level of Funding:	To develop a strategy for using integrative genomic analysis of prostate cancer PDXs to facilitate biomarker-driven clinical trials.
Goals:	Over the long term, we expect our approach to improve upon the strategy for testing therapeutic agents for prostate cancer, aid in patient care, and facilitate the development of personalized therapies for prostate cancer.
Specific Aims:	1) Develop PDXs that reflect the lethal form of prostate cancer. 2) Develop a responder ID profile hypothesis according to the treatment

responsiveness of fully characterized prostate cancer PDXs. 3) Validate the responder ID profile hypothesis in a clinical trial.
Role: Principal Investigator

R01 CA193362-01A1
Title: (Yang)
Role of Integrin VLA-6 in Suppression of Bone Formation in Myeloma

Time Commitment: 5% effort, 0.60 calendar
Supporting Agency: NIH/NCI
Grants Officer: LeSchell D. Browne, Grants Management Specialist

Performance Period: 02/01/2016-01/31/2021

Level of Funding:

Goals: To investigate the mechanism by which myeloma cells alter the balance of adipogenesis and osteoblastogenesis, thereby suppressing bone formation.

Specific Aims: 1) Determine whether the $\alpha 6$ integrin in myeloma cells enhances adipogenesis and suppresses osteoblastogenesis and bone formation. 2) Determine whether $\alpha 6$ in myeloma cells binds to its ligand in MSCs to activate a signaling pathway(s) that enhances adipocyte and inhibits osteoblast differentiation.

Role: Co-Investigator

2 P50 CA140388-06A1
Title: (Logothetis/Thompson)
MD Anderson Cancer Center Prostate Cancer SPORE – Core 2: Biospecimen and Pathology Core

Time Commitment: 5% effort, 0.60 calendar
Supporting Agency: NIH/NCI
Grants Officer: Leslie Hickman

Performance Period:

Level of Funding: 09/01/2016-08/31/2021

Goals: The overall goal of this Core is to provide the infrastructure, biorepository, xenograft facility, pathological and technical expertise, and informatic infrastructure required to support the projects of the MD Anderson Prostate Cancer SPORE and ensure the achievement of their goals.

Specific Aims: 1) Collect, process, annotate, characterize, store, and distribute human biospecimens related to prostate cancer. 2) Create well-characterized and quality-controlled tissue derivatives (including patient-derived xenografts) for translational research and conduct selected tissue-based studies. 3) Provide investigators with expertise to optimally select and use biospecimen resources, analytical techniques, and interpretation of tissue-based studies. 4) Provide an informatics solution (Prometheus) that tightly integrates biospecimen acquisition, annotation, and analysis workflows with clinical data in a secure and accessible manner.

Role: Co-Investigator, Core 2

OVERLAP: None

ARAUJO, John

CURRENT

2 P50 CA140388-06A1

Title:

(Logothetis and Thompson)

MD Anderson Cancer Center Prostate Cancer SPORE.

Project 2: Targeting Tumor Microenvironment-induced Therapy Resistance in Prostate Cancer Bone Metastasis

Time Commitment:

5%, 0.60 CM

Supporting Agency:

NIH/NCI

Grants Officer:

Leslie Hickman,

Performance Period:

09/01/2016-08/31/2021

Level of Funding:

Project Goals:

Our objectives are to develop strategies that can block osteocrine-mediated therapy resistance to enhance treatment efficacy.

Specific Aims:

1) Examine the ability of osteocrines to confer therapy resistance through activation of FAK. 2) Examine the effects of second-generation FAK inhibitors (VS-6063 or VS-4718) on overcoming osteocrine-induced therapy resistance in xenograft mouse models. 3) Conduct a clinical trial to examine the toxicity and efficacy of a FAK inhibitor (VS-6063 or VS-4718) in men with treatment-refractory bone-metastatic castrate-resistant prostate cancer.

Role:

Clinical Co-Leader, Project 2

OVERLAP: None

BROOM, Bradley

CURRENT

PCa Moon Shot

Title:

(Logothetis and Thompson)

MD Anderson Moon Shot Program

Pilot Project 1: Identification of differentially expressed biomarkers in biospecimens derived from men with indolent versus aggressive prostate cancer

Pilot Project 3: Imaging local prostate cancer heterogeneity by monitoring citrate acid cycle metabolites and cholesterol precursor metabolites

Time Commitment:

10% effort, 1.20 calendar

Supporting Agency:

MD Anderson Cancer Center, Prostate Cancer Moon Shot

Grants Officer:

Claudia Delgado, Executive Director, Grants and Contracts

Performance Period:

09/01/2016-08/31/2017

Level of Funding:

To reduce prostate cancer mortality through intensive novel androgen signaling inhibitor-based clinical trials, unprecedented tissue resources, and the development of novel concepts for the advancement of targeted therapy-based clinical trials for treatment refractory disease.

Project Goals:

Same as above

Specific Aims:

Co-Investigator

Role:

W81XWH-14-1-0554	(Navone)
Title:	Development of Personalized Cancer Therapy for Men with Advanced Prostate Cancer
Time Commitment:	2% effort, 0.24 calendar
Supporting Agency:	DOD-PCRP Synergistic Idea Development Award
Grants Officer:	Janet P. Kuhns, Contracting Officer
Performance Period:	09/22/2014-09/21/2017
Level of Funding:	
Project Goals:	The goal of this project is to develop a strategy for using integrative genomic analysis of prostate cancer PDXs to facilitate biomarker-driven clinical trials. Over the long term, we expect our approach to improve upon the strategy for testing therapeutic agents for prostate cancer, aid in patient care, and facilitate the development of personalized therapies for prostate cancer.
Specific Aims:	1) Develop PDXs that reflect the lethal form of prostate cancer. 2) Develop a responder ID profile hypothesis according to the treatment responsiveness of fully characterized prostate cancer PDXs. 3) Validate the responder ID profile hypothesis in a clinical trial.
Role:	Co-Investigator
5 P30 CA016672-40	(DePinho)
Title:	Cancer Center Support Grant
Time Commitment:	39% effort, 4.68 calendar
Supporting Agency:	NIH/NCI
Grants Officer:	Hasnaa Shafik, Program Director
Performance Period:	07/01/2003-06/30/2018
Level of Funding:	
Project Goals:	The goal of this shared resource is to assist researchers in the application of state-of-the-art methodology for the development, conduct, and analysis of studies using high-throughput technologies. Effort added.
Specific Aims:	Same as above.
Role:	Co-Investigator
01	(Weinstein)
Title:	MD Anderson Cancer Center Bioinformatics Gift
Time Commitment:	15.08% effort, 1.81 calendar
Supporting Agency:	Michael and Susan Dell Foundation
Grants Officer:	Aliya Hussaini P.O. Box 163867 Austin, TX 78716
Performance Period:	04/25/2011-10/04/2017
Level of Funding:	
Project Goals:	The goal of the project is to develop methods of analysis for microarray and sequencing-based data that aid in the development of personalized therapies for cancer on the basis of molecular biomarkers

Specific Aims: and biosignatures. The projects under way are largely, but not exclusively focused on non-small cell lung cancer.
 Role: Same as above
 Investigator

P50 CA140388-06A1
Title: **(Logothetis and Thompson)**
MD Anderson Cancer Center Prostate Cancer SPORE

Core 1: Biostatistics and Bioinformatics

Time Commitment: 13.5% effort, 1.62 calendar

Supporting Agency: NIH/NCI

Grants Officer: Leslie Hickman

Performance Period: 09/01/2016-08/31/2021

Level of Funding:

Project Goals: The Biostatistics and Bioinformatics Core provides comprehensive biostatistic and bioinformatic expertise to ensure statistical integrity and optimize data analysis for the studies in the SPORE.

Specific Aims: 1) Provide guidance in the design and conduct of clinical trials and other experiments (including high-dimensional genomic and proteomic studies) that arise from the ongoing research of the SPORE. 2) Provide innovative and tailored statistical modeling, simulation techniques, and data analyses as needed for the main projects, developmental research and career development projects, and other cores to achieve their specific aims. 3) Ensure that the results of all projects are based on well-designed experiments and are appropriately interpreted. 4) Provide guidance in the design and use of an information system to store appropriate data generated by all projects; develop integrated computational libraries and tools for producing documented, reproducible statistical and bioinformatics analyses; and support the use of these tools for analyses conducted by and on behalf of the projects.

Role: Co-Investigator

OVERLAP: None

UNIVERSITY OF MICHIGAN KEY PERSONNEL

CHINNAIYAN, Arul M.

CURRENT

U01 CA214170

Title: **(Chinnaiyan, Tomlins)**
The Early Detection Research Network: Biomarker Development Laboratories (U01): *Discovery and qualification of transcriptomic biomarkers for the early detection of aggressive prostate cancer*

Time Commitment: 15% effort, 1.80 calendar

Supporting Agency: NIH/NCI

Grants Officer: Peter Wirth

Performance Period: 09/01/2016-08/31/2021

Level of Funding:

Project Goals/Aims: 1) Identify and develop assays to study novel aggressive prostate cancer-associated transcriptomic alterations from our MiTranscriptome

analysis. 2) Characterize transcripts from Aim 1 as tissue based aggressive prostate cancer biomarkers using individual in situ hybridization assays and a multiplexed next generation sequencing (NGS). 3) Characterize transcripts from Aim 1 as non-invasive, urine-based aggressive prostate cancer early detection biomarkers through collaboration with our industry partner and multiplexed NGS.

R01 CA200660

Title:

(Grembecka, Chinnaiyan)

Targeting the MLL complex in Castration Resistant Prostate Cancer

Time Commitment:

10% effort, 1.20 calendar

Supporting Agency:

NIH

Grants Officer:

Elesinmogun, Funmi

Performance Period:

08/01/2016-07/31/2021

Level of Funding:

Project Goals:

To develop new therapy for castration resistant prostate cancer patients by blocking the menin-MLL interaction.

Specific Aims:

1) Develop highly potent small molecule inhibitors of the menin-MLL interaction with significantly improved potency in prostate cancer models and optimal in vivo properties. 2) we propose to study the mechanism of pharmacologic inhibition of the MLL complex in prostate cancer cells 3) we will assess the in vivo efficacy of the menin-MLL inhibitors in mice models of prostate cancer and investigate the mechanism of resistance of response to these compounds in prostate cancer models. Upon successful completion of this project we expect to identify promising candidate compound(s) that could be further developed for clinical use to treat metastatic CRPC.

U24 CA210967

Title:

(Nesvishkii and Chinnaiyan)

University of Michigan Proteogenomics Data Analysis Center

Time Commitment:

8% effort, 0.96 calendar

Supporting Agency:

NIH

Grants Officer:

Rodriguez, Henry

Performance Period:

09/15/2016-08/31/2021

Level of Funding:

Project Goals:

To perform integrative analysis of data generated using the Clinical Proteomic Tumor Analysis Consortium (CPTAC). The proposed Center at the University of Michigan will be one of the four Centers funded by CPTAC. It will work, in coordination with other Centers, to analyze and integrate proteomics, genomics, and transcriptomics data generated for 3-4 cancer patient cohorts, ~ 100 samples in each cohort. The Center will generate data analysis reports to be shared with other members of the Consortium.

Specific Aims:

1) Assemble a comprehensive proteogenomics data analysis pipeline enabling application of two complementary strategies: (a) using mass spectrometry-based (MS) proteomics data for protein-level "validation" (and thus prioritization) of novel and aberrant cancer-

specific transcripts (including alternative splice forms, mutations, etc.) identified from genomics and transcriptomic data.

2) Apply our computational pipelines to CPTAC-wide data, with a focus on presenting the results to the cancer research community in an easily accessible, highly visual form.

3) UM-PGDAC will engage, in coordination with other CPTAC centers, in a second round of prioritization work to select candidate cancer-specific proteins and peptides for subsequent targeted validation using multiplex proteomic assays.

U01 CA183027

Title:

Time Commitment:

Supporting Agency:

Grants Officer:

(Chinnaiyan, Linehan)

Integrative Molecular Imaging and Sequencing of Prostate Cancer

10% effort, 1.20 calendar

NIH

Lori A. Henderson

Performance Period:

02/11/2014-01/31/2017

Level of Funding:

Project Goals:

1) Enroll patients with known or suspicious for prostate cancer in the NIH MRI/metabolic imaging program, 2) Whole exome and transcriptome sequencing analysis of 60 patients identified with clinically localized prostate cancer from frozen biopsy material obtained in Aim 1. 3) Integrative analysis of histopathology, molecular imaging, metabolism, mutational landscape and gene expression alterations of biopsy material from this clinical trial.

Specific Aims:

Same as above.

UM1 HG006508

Title:

Time Commitment:

Supporting Agency:

Grants Officer:

Performance Period:

Level of Funding:

Project Goals:

(Chinnaiyan, Pienta, and Robert)

Exploring Precision Cancer Medicine for Sarcoma and Rare Cancers

10% effort, 1.20 calendar

NIH

Zephaun Harvey

07/19/2013-05/31/2017

The overall goal of this project is to bring together expertise at the University of Michigan including clinical oncology, cancer genetics, genomic science/bioinformatics, clinical pathology, social and behavioral sciences, and bioethics in order to implement clinical cancer sequencing of patients with sarcomas and other rare cancers to enable the detection of clinically significant molecular lesions (point mutations, insertions/deletions, gene fusions and rearrangements, outlier expressed genes, and amplifications/deletions).

Specific Aims:

Project 1: Clinical Genomic Study, 1) Accrue 500 patients with advanced or refractory rare cancer for participation in an integrated approach to Clinical Genomics; 2) Interpret results through a multi-disciplinary Sequencing Tumor Board and disclose results to patients and their physicians; 3) Measure the influence of sequence results provided to patients; 4) Determine the frequency of clinically

significant germline mutations in patients undergoing comprehensive tumor sequence analysis.

Project 2: Sequencing, Analysis, and Interpretation of Sequencing Data; 1) Process and track specimens and ensure quality control; 2) Sequence tumor and germline biospecimens; 3) Analyze sequencing data to identify clinically significant variants; 4) Interpret and translate sequence variants into clinical oncology setting; 5) Assess and evaluate costs associated with clinical sequencing.

W81XWH-12-1-0080

(Chinnaiyan)

Title:

Advancing Our Understanding of the Etiologies and Mutational Landscapes of Basal-Like, Luminal A, and Luminal B Breast Cancers

Time Commitment:

7.50% effort, 0.90 calendar

Supporting Agency:

DOD – Collaborative Innovators Award

Grants Officer:

Cheryl A. Lowery

Performance Period:

09/15/2012-09/14/2017

Level of Funding:

Project Goals:

Sequencing of the samples to find mutations; correlate with clinical pathologic and epidemiologic factors.

Specific Aims:

1) Identify and quantify risk factors for each of the most common molecular subtypes of breast cancer, basal-like, luminal A, and luminal B tumors, in a large-scale population-based study. 2) Discover and validate the mutational landscape of basal-like, luminal A, and luminal B tumors. 3) Characterize the relationships between subtype specific risk factors and mutational signatures. 4) Develop and validate risk prediction models unique to each breast cancer subtype incorporating clinical, epidemiologic and mutation data. 5) Identify and quantify the relationships between various exposures and mutational changes on risk of breast cancer recurrence and survival among patients with basal-like, luminal A, and luminal B tumors.

W81XWH-14-1-0555

(Chinnaiyan, Navone)

Title:

Development of Personalized Cancer Therapy for Men with Advanced Prostate Cancer

Time Commitment:

5% effort, 0.60 calendar

Supporting Agency:

DOD

Grants Officer:

Peggie Lesnow

Performance Period:

09/22/2014-09/21/2017

Level of Funding:

Project Goals:

To develop a strategy for identifying molecular therapeutic response markers of advanced prostate cancer to specific therapies by using patient-derived xenografts (PDXs) from patients with prostate cancer.

Specific Aims:

1) Develop PDXs that reflect the lethal form of prostate cancer; 2) Develop a responder ID profile hypothesis according to the treatment responsiveness of fully characterized prostate cancer PDXs; 3) Validate the responder ID profile hypothesis in a clinical trial.

U01 HL126499**Title:****(Tewari)****Reference Profiles of ExRNA in Biofluids from Well-Defined Human Cohorts**

Time Commitment:

4% effort, 0.48 calendar

Supporting Agency:

NIH/NHLBI

Grants Officer:

Tracee Foster

Performance Period:

08/01/2014-04/30/2019

Level of Funding:

Project Goals:

To generate quality-controlled, comprehensive RNA sequencing-based profiles of human body fluids including plasma, serum and urine from healthy individuals.

Specific Aims:

1) To sequence exRNAs present in biofluids of healthy individuals. 2) To identify and annotate both endogenously and exogenously-derived exRNA sequences. 3) To perform validation and absolute quantification of exRNAs using droplet digital PCR (ddPCR). 4) To perform cross-validation service and integrate scientifically with other Consortium teams.

Role:

Co-Investigator

P50 CA186786**Title:****(Chinnaiyan)****SPORE in Prostate Cancer**

Project 1: A Precision Medicine Approach to Elucidate Mechanisms of Progression and Resistance to Therapy in Advanced Prostate Cancer.

Project 4: Development of lncRNAs as Prostate Cancer Biomarkers in Urine

Core 3: Tissue Core

Time Commitment:

20% effort, 2.40 calendar

Supporting Agency:

NIH/NCI

Grants Officer:

Andrew Hruszkewycz

Performance Period:

09/11/2014-08/31/2019

Level of Funding:

Project Goals:

The overall goal of this grant is the development of new approaches to the prevention, early detection, diagnosis and treatment of prostate cancer through translational research.

Specific Aims:

Project 1 Aims: 1) Discovery and nomination of novel molecular sub-types of prostate cancer; 2) Characterize associations of molecular sub-types of prostate cancer with clinical outcome and/or aggressiveness of disease in a radical prostatectomy cohort; 3) Characterize associations of molecular sub-types of prostate cancer with clinical outcome. *Project 4 Aims:* 1) Employ a compendium of prostate cancer RNA-Seq data to nominate lncRNAs for assessment in urine. 2) Develop a urine multiplex panel of lncRNAs (including PCAS and Schalpl) that, when combined with TMPRSS2-ERG, will identify men who are more likely to have prostate cancer and ultimately to prevent unnecessary prostate biopsies in men with a low likelihood of cancer. 3) Define a panel of lncRNAs in urine for the detection of high grade prostate cancer. In this Aim, we will identify individual lncRNAs or combinations with PGAS +TMPRSS2-ERG that assist in non-invasively detecting high grade prostate cancer in urine.

Core 3 aims: 1) To protect patient welfare; 2) The acquisition and processing of prostate tissues for research; 3) The maintenance of clinical and pathology data with links to molecular studies; To provide high quality pathologic review of prostate tissues; 5) To provide expert pathology consultation; 6) To perform quality assessment of prostate tissues and clinical data; 7) To develop technology appropriate for pathology-based translational research.

Roles: Overall Program Director, Co-Leader of Projects 1 and 4; Director of Core 1 (Administration) and Co-Core Director of Core 3 (Tissue Core)

OVERLAP: None

ROBINSON, Dan
CURRENT

U01 CA183027

Title:
Time Commitment:
Supporting Agency:
Grants Officer:

(Chinnaiyan and Linehan)

Integrative Molecular Imaging and Sequencing of Prostate Cancer
7% effort, 0.84 calendar
NIH
Lori A. Henderson

Performance Period:
Level of Funding:
Project Goals:

02/11/2014-01/31/2017

1) Enroll patients with known or suspicious for prostate cancer in the NIH MRI/metabolic imaging program, 2) Whole exome and transcriptome sequencing analysis of 60 patients identified with clinically localized prostate cancer from frozen biopsy material obtained in Aim 1. 3) Integrative analysis of histopathology, molecular imaging, metabolism, mutational landscape and gene expression alterations of biopsy material from this clinical trial.

Specific Aims:
Role:

Same as above.
Co-Investigator

UM1 HG006508

Title:

(Chinnaiyan, Pienta, and Robert)

Exploring Precision Cancer Medicine for Sarcoma and Rare Cancers

Time Commitment:
Supporting Agency:
Grants Officer:
Performance Period:
Level of Funding:
Project Goals:

15% effort, 1.80 calendar
NIH
Zephaun Harvey
07/19/2013-05/31/2017

The overall goal of this project is to bring together expertise at the University of Michigan including clinical oncology, cancer genetics, genomic science/bioinformatics, clinical pathology, social and behavioral sciences, and bioethics in order to implement clinical cancer sequencing of patients with sarcomas and other rare cancers to enable the detection of clinically significant molecular lesions.

Specific Aims:

Project 1: Clinical Genomic Study, 1) Accrue 500 patients with advanced or refractory rare cancer for participation in an integrated approach to Clinical Genomics; 2) Interpret results through a multi-

disciplinary Sequencing Tumor Board and disclose results to patients and their physicians; 3) Measure the influence of sequence results provided to patients; 4) Determine the frequency of clinically significant germline mutations in patients undergoing comprehensive tumor sequence analysis.

Project 2: Sequencing, Analysis, and Interpretation of Sequencing Data; 1) Process and track specimens and ensure quality control; 2) Sequence tumor and germline biospecimens; 3) Analyze sequencing data to identify clinically significant variants; 4) Interpret and translate sequence variants into clinical oncology setting; 5) Assess and evaluate costs associated with clinical sequencing.

Role: Co-Investigator

W81XWH-14-1-0555

**Title: (Chinnaiyan, Navone)
Development of Personalized Cancer Therapy for Men with Advanced Prostate Cancer**

Time Commitment: 16% effort, 1.92 calendar

Supporting Agency: DOD

Grants Officer: Peggie Lesnow

Performance Period: 09/22/2014-09/21/2017

Level of Funding: To develop a strategy for identifying molecular therapeutic response markers of advanced prostate cancer to specific therapies by using patient-derived xenografts (PDXs) from patients with prostate cancer.

Project Goals: 1) Develop PDXs that reflect the lethal form of prostate cancer; 2) Develop a responder ID profile hypothesis according to the treatment responsiveness of fully characterized prostate cancer PDXs; 3) Validate the responder ID profile hypothesis in a clinical trial.

Specific Aims: Co-Investigator

W81XWH-12-1-0080

**Title: (Chinnaiyan)
Advancing Our Understanding of the Etiologies and Mutational Landscapes of Basal-Like, Luminal A, and Luminal B Breast Cancers**

Time Commitment: 10% effort, 1.20 calendar

Supporting Agency: DOD – Collaborative Innovators Award

Grants Officer: Cheryl A. Lowery

Performance Period: 09/15/2012-09/14/2017

Level of Funding:

Project Goals: Sequencing of the samples to find mutations; correlate with clinical pathologic and epidemiologic factors.

Specific Aims: 1) Identify and quantify risk factors for each of the most common molecular subtypes of breast cancer, basal-like, luminal A, and luminal B tumors, in a large-scale population-based study. 2) Discover and validate the mutational landscape of basal-like, luminal A, and luminal B tumors. 3) Characterize the relationships between subtype specific risk factors and mutational signatures. 4) Develop and validate risk

prediction models unique to each breast cancer subtype incorporating clinical, epidemiologic and mutation data. 5) Identify and quantify the relationships between various exposures and mutational changes on risk of breast cancer recurrence and survival among patients with basal-like, luminal A, and luminal B tumors.

Role: Co-Investigator

P50 CA186786

Title:

(Chinnaiyan)

SPORE in Prostate Cancer, Project 1: A Precision Medicine Approach to Elucidate Mechanisms of Progression and Resistance to Therapy in Advanced Prostate Cancer

Time Commitment:

16% effort, 1.92 calendar

Supporting Agency:

NIH/NCI

Grants Officer:

Andrew Hruszkewycz

Performance Period:

09/11/2014-08/31/2019

Level of Funding:

Project Goals:

1) Discovery and nomination of novel molecular sub-types of prostate cancer; 2) Characterize associations of molecular sub-types of prostate cancer with clinical outcome and/or aggressiveness of disease in a radical prostatectomy cohort; 3) Characterize associations of molecular sub-types of prostate cancer with clinical outcome

Specific Aims:

Same as above.

Role:

Co-Investigator

OVERLAP: None

WU, Yi-Mi

CURRENT

U01 CA183027

Title:

(Chinnaiyan, Linehan)

Integrative Molecular Imaging and Sequencing of Prostate Cancer

Time Commitments:

20% effort, 2.40 calendar

Supporting Agency:

NIH/NCI

Grants Officer:

Lori A. Henderson

Performance Period:

02/11/2014-01/31/2017

Level of Funding:

Goals:

1) Enroll patients with known or suspicious for prostate cancer in the NIH MRI/metabolic imaging program, 2) Whole exome and transcriptome sequencing analysis of 60 patients identified with clinically localized prostate cancer from frozen biopsy material obtained in Aim 1. 3) Integrative analysis of histopathology, molecular imaging, metabolism, mutational landscape and gene expression alterations of biopsy material from this clinical trial.

Specific Aims:

Same as above

Role:

Co-Investigator

W81XWH-14-1-0555

Title:

(Chinnaiyan)

Development of Personalized Cancer Therapy for Men with Advanced Prostate Cancer

Time Commitments: 30.00% effort, 3.60 calendar
Supporting Agency: DOD
Grants Officer: Peggie Lesnow

Performance Period: 09/22/2014-09/21/2017
Level of Funding: to develop a strategy for identifying molecular therapeutic response
Project Goals: markers of advanced prostate cancer to specific therapies by
using patient-derived xenografts (PDXs) from patients with prostate
cancer.

Specific Aims: 1) Develop PDXs that reflect the lethal form of prostate cancer; 2)
Develop a responder ID profile hypothesis according to the treatment
responsiveness of fully characterized prostate cancer PDXs; 3)
Validate the responder ID profile hypothesis in a clinical trial.
Role: Co-Investigator

W81XWH-12-1-0080 (Chinnaiyan)
Title: **Advancing our Understanding of The Etiologies and Mutational
Landscapes of Basal-Like, Luminal A, and Luminal B Breast
Cancers**

Time Commitments: 10% effort, 1.20 calendar
Supporting Agency: DOD
Grants Officer: Cheryl A. Lowery

Performance Period: 09/15/2012-09/14/2017
Level of Funding:
Goals: Define the Mutational Landscapes of Breast Cancer
Specific Aims:

1) Identify and quantify risk factors for each of the most common
molecular subtypes of breast cancer, basal-like, luminal A, and luminal
B tumors, in a large-scale population-based study. 2) Discover and
validate the mutational landscape of basal-like, luminal A, and luminal
B tumors. 3) Characterize the relationships between subtype specific
risk factors and mutational signatures. 4) Develop and validate risk
prediction models unique to each breast cancer subtype incorporating
clinical, epidemiologic and mutation data. 5) Identify and quantify the
relationships between various exposures and mutational changes on
risk of breast cancer recurrence and survival among patients with
basal-like, luminal A, and luminal B tumors.
Role: Research Specialist

5 P50 CA186786 (Chinnaiyan)
Title: **SPORE in Prostate Cancer, Project 1: A Precision Medicine
Approach to Elucidate Mechanisms of Progression and Resistance
to Therapy in Advanced Prostate Cancer**

Time Commitments: 10% effort, 1.20 calendar
Supporting Agency: NIH/NCI
Grants Officer: Andrew Hruszkewycz

Performance Period: 09/11/2014-08/31/2019
Level of Funding:

Goals: 1) Discovery and nomination of novel molecular sub-types of prostate cancer; 2) Characterize associations of molecular sub-types of prostate cancer with clinical outcome and/or aggressiveness of disease in a radical prostatectomy cohort; 3) Characterize associations of molecular sub-types of prostate cancer with clinical outcome.

Specific Aims: Same as above

Role: Research Investigator

OVERLAP: None

What other organizations were involved as partners?

The Partnering PI, Dr. Arul Chinnaiyan, is from the University of Michigan. Drs. Chinnaiyan and Navone as well as the University of Michigan and MD Anderson teams worked closely to design and interpret the studies performed during the period of this progress report. Partnering PI performed all next generation sequencing studies and also made available the results in a timely manner as well as the software and knowledge necessary to the interpretation of next generation sequencing results by the MD Anderson team.

Partnering PI Location: The University of Michigan
400 E. Medical Center Drive
5316 CCC
Ann Arbor, MI 48109-5940

SPECIAL REPORTING REQUIREMENTS

Not Applicable

COLLABORATIVE AWARDS: For collaborative awards, independent reports are required from BOTH the Initiating Principal Investigator (PI) and the Collaborating/Partnering PI. A duplicative report is acceptable; however, tasks shall be clearly marked with the responsible PI and research site.